Autolus Therapeutics plc (AUTL) stock
AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3020% below fair value
$1.09−0.05 (-4.39%)
Close on Nov 17, 2026Market cap $290.12MP/E –Yield –
Autolus Therapeutics cash
Cash and short-term investments held at the end of each period.
Autolus Therapeutics's cash was $201.63M at Jun 30, 2026. For fiscal 2025 it was $300.71M, down 49.0% from the year before. The highest annual figure on record is $589.45M in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $300.71M | -49.0% |
| FY2024 | Dec 31, 2024 | $589.45M | +145.3% |
| FY2023 | Dec 31, 2023 | $240.34M | -37.2% |
| FY2022 | Dec 31, 2022 | $382.76M | +23.3% |
| FY2021 | Dec 31, 2021 | $310.34M | +101.4% |
| FY2020 | Dec 31, 2020 | $154.09M | -37.6% |
| FY2018 | Sep 30, 2018 | $246.98M | +80.2% |
| FY2017 | Sep 30, 2017 | $137.07M | +388.5% |
| FY2016 | Sep 30, 2016 | $28.06M | +175.0% |
| FY2015 | Sep 30, 2015 | $10.20M | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $201.63M | -55.6% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $229.43M | -55.6% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $300.71M | -49.0% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $367.41M | -44.1% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $454.28M | -35.6% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $516.58M | -31.9% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $589.45M | +145.3% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $657.07M | +156.3% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $705.94M | +129.6% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $758.53M | +121.1% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $240.34M | -37.2% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $256.42M | +57.3% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $307.50M | +42.1% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $343.03M | +27.7% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $382.76M | +23.3% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $163.05M | -31.8% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $216.44M | +40.5% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $268.56M | +51.1% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $310.34M | +46.4% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $239.01M | -1.8% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $154.09M | -37.6% |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $177.70M | -32.9% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | $212.04M | +64.4% |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $243.31M | +77.5% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $246.98M | +780.2% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $264.92M | +2496.5% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $128.98M | – |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $137.07M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $28.06M | – |
| Q4 FY2015CQ3 2015 | Sep 30, 2015 | $10.20M | – |
See a number that looks wrong?